Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. (VTAK) is a U.S.-based medical device company focused on the cardiac electrophysiology market, and its news flow reflects developments around its VIVO 3D imaging system and LockeT suture retention device. The company’s releases highlight product adoption, regulatory milestones, financial updates, and corporate actions relevant to investors and clinicians following VTAK stock.
Recent news has emphasized international expansion for both VIVO and LockeT. Catheter Precision has reported tender wins and first purchase orders for the VIVO system at hospitals such as Albert Szent‑Györgyi Health Centre in Hungary and Dubrava University Hospital in Croatia, following evaluations against competing technologies. For LockeT, the company has announced launches in Switzerland and South Africa, distribution agreements with regional partners, and implementation at major electrophysiology centers, including Mater Private Hospital in Dublin, Ireland.
In addition to commercial updates, Catheter Precision issues releases on financial results, furnished on Form 8‑K, summarizing revenue trends and operating performance for specific quarters and year‑to‑date periods. The company also uses news announcements to discuss regulatory and reimbursement developments that may affect the use of its products, such as changes in procedure coverage for ambulatory surgery centers that it views as relevant to LockeT utilization.
Other news items cover intellectual property developments, including allowance of patents related to ventricular arrhythmia localization and neurostimulation devices, as well as corporate and capital markets events like reverse stock splits, at‑the‑market offering programs, and stockholder meetings. For ongoing insight into VTAK, this news page aggregates these updates so readers can follow Catheter Precision’s product adoption, geographic reach, financial disclosures, and key regulatory or governance events over time.
Catheter Precision (NYSE American:VTAK) has secured $4.9 million in gross proceeds through warrant exercises. The company entered into a definitive agreement for the immediate exercise of Series E, F, G, H, and I warrants to purchase 5,347,981 shares at a reduced price of $0.70 per share, generating $3.7 million. An additional $1.185 million was received through warrant exercises in the past week. In exchange, the company will issue new unregistered Series K warrants for up to 10,695,962 shares at $0.70, exercisable after shareholder approval with a 5.5-year term.
Catheter Precision (NYSE American:VTAK) announced two presentations featuring their VIVO technology at the International Society for Cardiac Robotic Navigation Meeting in Lisbon, Portugal, October 28-29. Dr. Jack Griffiths from Royal Brompton Hospital will present on 'Robotics in VT plus non-invasive 3D mapping', focusing on time-saving data. Peter van Dam, PhD will discuss 'Non-invasive Mapping Using Individual Anatomy', highlighting VIVO's patient-specific advantages. Dr. Leonor Perriera will present updates from the VIVO European Registry, including acute success and 12-month follow-up data for ventricular ablation.
Catheter Precision, Inc. (NYSE American:VTAK) has announced a new publication in the October 2024 issue of HeartRhythm Case Reports, highlighting the use of their VIVO technology in a novel, non-invasive ablation technique called stereotactic radioablation (STAR). The procedure, which uses external photon beams to target and ablate areas of the heart responsible for arrhythmia, demonstrated success in a patient unresponsive to traditional ablation for ventricular tachycardia.
Key highlights include:
- VIVO played a fundamental role in identifying the VT origin within the scar
- VIVO provided a more precise location than traditional 12-lead ECG methods
- After a 4-month follow-up, the patient reported no new episodes of VT or heart failure
CEO David Jenkins emphasized the potential of VIVO as a non-invasive, patient-specific, pre-procedural planning tool for improving procedural outcomes in non-invasive ablation treatments.
Catheter Precision (NYSE/American:VTAK) announced its participation in the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16-18 in Paris, France. ISCAT is a biannual European meeting focusing on new and emerging catheter ablation technologies, techniques, and study data for atrial and ventricular arrhythmias.
CEO David Jenkins emphasized the importance of attending such meetings as part of their sales strategy, stating that it provides an opportunity to meet physicians, showcase technologies, and generate new sales leads. At ISCAT, Catheter Precision plans to demonstrate their VIVO technology and highlight recent clinical data presented at the European Society of Cardiology meeting in September, which demonstrates VIVO's value and accuracy.
Catheter Precision, Inc. (NYSE/American:VTAK), a US-based medical device company specializing in cardiac electrophysiology products, has announced its participation in the 19th annual International VT Symposium on October 11-12 in New York City. The symposium, hosted by the Hospital at the University of Pennsylvania and Mount Sinai Hospital, focuses on new management strategies for ventricular arrhythmias, including nonpharmacological therapies like implantable devices and catheter ablation techniques.
David Jenkins, CEO of Catheter Precision, emphasized the importance of this event, stating it provides an opportunity to interact with a specialized group of physicians treating ventricular arrhythmias. The company's VIVO product enables better planning of ventricular ablation procedures, potentially reducing procedural time and patient complications. Catheter Precision aims to share new data and product improvements with attendees during the symposium.
Catheter Precision (NYSE/American:VTAK) has announced updates for their VIVO non-invasive mapping system. At the European Society of Cardiology (ESC) meeting, Prof. Tarv Dhanjal presented data from a 20-patient study, showing 90% procedural success at a mean follow-up of 7.3 ± 4.7 months in patients with scar-related VT. The full study, expected to enroll 50 patients, is anticipated to conclude in 2025.
Catheter Precision will showcase VIVO at several conferences in October, including the International VT Symposium, ISCAT, and SCRN. The company is expanding its commercial footprint, with over 25 centers confirming interest and eight new centers scheduled for evaluations. Additionally, following a successful evaluation in Doha, Qatar, the hospital has acquired and installed the VIVO system, completing its first commercial procedures.
Catheter Precision, Inc. (VTAK:NYSE/American) has announced the issuance of its first LockeT patent in China. LockeT is a suture retention device used for closing percutaneous catheter access sites during various procedures, including electrophysiology, structural heart, and vascular surgery. The device is currently sold in the US and select international markets.
The company is awaiting CE mark certification, expected in Q1 2025, which will allow access to the European market. CEO David Jenkins highlighted China as a significant market for LockeT, citing its low-cost alternative status and clinical data demonstrating ease of use, patient comfort, and effectiveness in groin management, including early ambulation and same-day discharge.
Catheter Precision, Inc. (NYSE American: VTAK), a US-based medical device company specializing in electrophysiology products, has expanded its LockeT distribution to the Middle East. The company has signed a distribution agreement with Dubai-based Forum Medical, which includes partnerships with additional distributors in Georgia, Uzbekistan, and Kazakhstan.
LockeT is described as a safe, low-cost device that provides quick hemostasis after venous access, reducing time and staff-related burdens. CEO David Jenkins highlighted the product's high demand in both international and US markets, expressing excitement about introducing this unique tool to physicians in new regions.
Catheter Precision, Inc. (NYSE American: VTAK), a US-based medical device company specializing in cardiac electrophysiology, has announced its first purchase order for LockeT from the Pacific Northwest territory. The order comes from the MultiCare Health System, which operates 300 specialty care locations and twelve hospitals across Washington State, Idaho, and Oregon.
This development follows the company's recent expansion of its US sales and clinical team in preparation for the national product launch of LockeT. CEO David Jenkins expressed satisfaction with the continued growth from new hospitals and territories throughout the US, attributing it to the new sales, marketing, and growth strategy implemented earlier this year for LockeT.
Catheter Precision, Inc. (NYSE American:VTAK) announced interim results from a study presented at the European Society of Cardiology (ESC) Symposium. The study, led by Professor Tarv Dhanjal at Warwick Medical School, demonstrated the accuracy of VIVO in localizing ventricular tachycardia (VT) origin in patients with scar-related re-entrant VT. Key findings include:
- 90% accuracy of VIVO compared to invasive mapping
- Significant match in myocardial scar areas
- 90% procedural success at 7-month follow-up
- Study included patients with various cardiomyopathies and mean ejection fraction of 35.5%
CEO David Jenkins highlighted the significance of these results for treating complex cardiac patients and expressed hope for expanded indications in the US.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
